INVESTORS & MEDIA
News Release
Regeneron to Report Fourth Quarter and Full Year 2017 Financial and Operating Results and Host Conference Call and Webcast on February 8, 2018
Conference Call Information
To access this call, dial (800) 708-4539 (
About Regeneron
Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, including VelocImmune® to yield optimized fully-human antibodies, and ambitious initiatives such as the Regeneron Genetics Center, one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information: |
|
Investor Relations |
Corporate Communications |
|
|
914.847.5126 |
914.847.3422 |
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2017-financial-and-operating-results-and-host-conference-call-and-webcast-on-february-8-2018-300586890.html
SOURCE
News Provided by Acquire Media